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ACTUAL WEIGHT TO CALCULATE SURFACE AREA PROVIDES THE BEST
ESTIMATE OF AUC FOR MELPHALAN IN MYELOMA
Shaw, P.J.1,7, Nath, C.E.1, Trotman, J.2,7, Gurney, H.P.3, Zeng, L.1,
Kwan, Y.-L.2, Presgrave, P.4, Tiley, C.R.5, Joshua, D.E.6,7,
Kerridge, I.H.3, McLachlan, A.J.2,7, Earl, J.W.1 1Children’s Hospital
at Westmead, Sydney, NSW, Australia; 2Concord Hospital; 3Westmead
Hospital, Sydney, NSW, Australia; 4Wollongong Hospital, Australia;
5Gosford Hospital, Australia; 6Royal Prince Alfred Hospital, Australia;
7University of Sydney, NSW, Australia
High dose melphalan (MLP, 200 mg/m2) is an important treat-
ment for multiple myeloma, even in the era of novel biological
agents. The prevalence of obesity is increasing, but there is little in-
formation on how best to adjust the dose in obese patients.
Aim:Use pharmacokinetic data from 16 lean patients (body mass in-
dex, BMI# 25 kg/m2) and 36 obese patients (BMI$ 30 kg/m2) with
normal renal function (est Cr Cl. 60 mL/min) to evaluate alternate
size descriptors that best fit the actual drug exposure.
Methods: PlasmaMLP levels were measured in 6-12 blood samples
collected from 100 patients who had received a single high dose of
MLP (median:192 mg/m2). Individual results of MLP clearance
were determined using a two compartment model developed using
the NONMEM IV software. Subsequent analysis was restricted to
obese and lean patients with normal renal function. Two-sided
two-sample T-test was first used to compare MLP clearance of
lean and obese patients. Extrapolating from individual clearance
results, drug exposure (AUC) for obese patients (AUCobese) was pre-
dicted using the formula dose/clearance, where dose was calculated
either using actual body weight (ABW) in the formula for BSA or
alternate weight descriptors. The AUC for lean patients (AUClean)
used ABW in the BSA formula. The ratio of AUCobese: mean
AUClean was calculated and compared to unity (indicating equivalent
exposure for obese and lean patients) using a two-sided, one-sample
T-test. This analysis was repeated for each gender separately.
Results: MLP Clearance (L/h) is significantly higher in obese pa-
tients compared with lean patients (32.26 10.2 versus 26.16 6.2
L/h, p\0.05), but after normalisation to BSA using ABW, there is
no significant difference (15.96 4.8 versus 15.26 3.3 L/h/m2). Us-
ing ABW in the BSA formula to determine dose, AUCobese is (mean
6 s.d.) 13.66 3.9 mg/L.h, AUClean is 13.86 2.9 mg/L.h, resulting
in a ratio of 0.996 0.29, which is not significantly different from
1.0. All other weight descriptors in the BSA formula (predicted nor-
mal weight, ideal body weight, adjusted ideal body weight, lean body
mass and the mean of ideal and ABW) resulted in AUC ratios that
were significantly lower than 1.0 (p\0.05).
Conclusions: Use of ABW in the BSA formula to calculate dose
rather than alternate weight descriptors achieves equivalent exposure
to MLP in obese and lean patients. Continued follow up will assess
the significance of these levels in all weight groups.PEDIATRIC DISORDERS
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INTERNATIONAL MULTICENTER STUDY ANALYZING THE LONG TERM
OUTCOME OF HURLER SYNDROME PATIENTS AFTER SUCCESSFUL HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION
Aldenhoven, M.1, de Koning, T.J.2, Wraith, E.J.3, Wynn, R.F.4,
Boelens, J.J.1 1University Medical Center Utrecht, Netherlands; 2Uni-
versity Medical Center Utrecht, Netherlands; 3Royal Manchester Child-
ren’s Hospital, Manchester, United Kingdom; 4Royal Manchester
Children’s Hospital, Manchester, United Kingdom
Hurler syndrome (HS), the most severe phenotype in the spec-
trum of Mucopolysaccharidosis type I (MPS I), is caused by a severe
deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA).
HS is clinically characterized by a progressive and ultimately fatal
multi-system deterioration with involvement of the central nervous
system. At present, hematopoietic stem cell transplantation
(HSCT) is the only treatment able to prevent disease progression
in the central nervous system and therefore considered the treatment
of choice in HS.Successful donor engraftment in HS patients has shown to be
highly effective, although with variable outcome between trans-
planted patients. Since long term follow-up data are sparse, insight
in the long term outcome of successfully transplanted HS patients
and the influencing factors are still largely unknown. Recently, an in-
ternational multicenter study has been initiated analyzing the long
term outcome of successfully transplanted HS patients worldwide.
The primary outcome parameters consist of the neurocognitive/de-
velopmental and functional outcome. Secondary outcome parame-
ters include the outcome regarding the various organ systems (eg
orthopedic, cardiac, respiratory, ophthalmologic, etc) as well as the
quality of life and processes of care. This international study will in-
clude ‘alive and engrafted’ HS patients, with a follow up of at least
three years post-HSCT. These patients, approximately 200 (about
80% of the HS patients successfully transplanted worldwide), have
been transplanted between 1980 and 2006 at the leading transplan-
tation centers in Europe as well as theUnited States. From eight cen-
ters, with a total of 160 patients by the end of 2009, data collection is
already achieved. An update of the study will be presented during the
meeting.
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OUTCOMES OF TRANSPLANTATION USING A VARIOUS CELL SOURCE IN
CHILDREN WITH HURLERS SYNDROME AFTER MYELO-ABLATIVE CON-
DITIONING. AN EUROCORD-EBMT-CIBMTR COLLABORATIVE STUDY
Boelens, J.J.1, Aldenhoven, M.1, Purtill, D.2, Eapen, M.9, DeForr, T.9,
Wynn, R.3, Cavazanna-Calvo, M.4, Tolar, J.5, Prasad, V.K.6,
Escolar, M.7, Gluckman, E.2, Orchard, P.5, Veys, P.8, Kurtzberg, J.6,
Rocha, V.2 1UMC Utrecht, Utrecht, Netherlands; 2EUROCORD, Paris,
France; 3Royal Manchester Children’s Hospital, Manchester, United
Kingdom; 4Hopital Necker-Enfants Malades, Paris, France; 5University
of Minnesota,Minneapolis; 6Duke University, Durham, NC; 7University
of North Carolina, Chapel Hill; 8Great Ormond Street Hospital, London,
United Kingdom; 9CIBMTR, Milwaukee, WI
Hurlers syndrome (HS), the most severe form of mucopolysac-
charidosis type-I causes progressive deterioration of the central
nervous system and death in childhood. Allogeneic-stem cell trans-
plantation (SCT), if performed early halts disease progression and
prolongs life. Graft-failure and mixed-chimerism (40-50%) limit
the success of SCT in HS. Various cell sources including unrelated
cord blood have been used over the last decades. However, impact
of various cell sources (Matched Sibling donor; MSD, unrelated
donor; UD, unrelated cord blood; uCB and T-cell depleted UD;
TCDud) on outcomes of SCT in HS is not well studied. We have
analyzed 258 HS children that received a SCT after a myelo-ablative
conditioning regimen from 1995 to 2007 and were reported to
EUROCORD, EBMT or CIBMTR. Median age at SCT was 16.7
(2-228) months, and median follow up was 57 (1.3-140) months.
The donors were MSD (n5 37; 14%), UD (n5 52; 21%), uCB
(n5 116; 44%), TCDud (n5 53; 21%). All but 8 patients, received
a Busulfan-based myeloablative regimen. All patients receiving an
unrelated donor and 8 MSD received ATG (n5 207) or Campath
(n5 21).
Overall neutrophil recovery was 91+/-3% at day 60. Overall acute-
GvHD (grade II-IV) was observed in 26%, while chronic-GvHD
was seen in 12+/-3% at 5 years. Five years overall survival (OS)
and disease and event free survival (EFS) were 74% and 64%, respec-
tively. ForOS at 5 years, an age of\20months at SCTwas associated
with a higher survival (p5 0,04). OS was higher after MSD (92%),
compared to the other sources UD (76%; p5 0.078), uCB (74%;
p5 0,038) and TCDud (64%; p5 0,007). EFS at 5 years was similar
between MSD (81%), MUD (69%; p5 0,148) and uCB (67%;
p5 0,11) but lower after TCDud (38%; p\0.001). Of those who
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latest follow up time point (median 57mths: 6-140) was found in
21%. The highest rate of full donor chimerism was found in uCB
(93%), compared to 73% inMSD, 64% in UD and 75% in TCDud.
Normal enzyme levels at latest follow up time point were found in all
(100%) of the uCB, in 53% of MSD, in 74% of UD and in 75% of
TCDud recipients.
Outcomes following SCT is HS are encouraging. Younger age at
SCT is a predictor for higher OS. Regarding OS, MSD do better
compared to UD and uCB, but no difference was found for EFS.
TCDud is a predictor for lowerOS/EFS. uCB leads to higher donor-
chimerism levels and enzymes which is suggested to have a positive
impact on the long term outcomes.69
MYELOABLATIVE (MAC) AUTOLOGOUS STEM CELL TRANSPLANTATION
(AUTOSCT) FOLLOWED BY REDUCED INTENSITY (RIC) ALLOGENEIC
STEM CELL TRANSPLANTATION (ALLOSCT) IN CHILDREN, ADOLESCENTS
AND YOUNG ADULTS (CAYA) WITH POOR RISK HODGKIN’S LYMPHOMA
(HL): INDUCTION OF LONG TERM GVHL EFFECT
Cairo, M.S.1,2,3, Geyer, M.B.1, Harrison, L.1, Schonfeld, T.1,
Bhatia, M.1, Bradley, M.B.1, Garvin, J.H.1, George, D.1, Fearon, N.1,
Martin, P.4, Kurtzberg, J.4, Schwartz, J.2, Baxter-Lowe, L.A.5,
Satwani, P.1 1Morgan Stanley Childrens Hospital, New York-Presbyter-
ian Hospital, Columbia University, NY; 2Columbia University, New
York, NY; 3Columbia University, New York, NY; 4Duke University,
Durham, NC; 5University of California, San Francisco, CA
Background: Long-term EFS in CAYA with poor risk HL who
are induction failures or who relapse or progress following initial
therapy is poor (#30% 10 year EFS) due to relapse and secondary
MDS or malignancy (Bradley/Cairo et al., BMT, 2008). Recent
data in poor risk adult HL suggests a strong GVHL effect follow-
ing RIC AlloSCT (Peggs et al., Lancet, 2005 and Sureda et al.,
JCO, 2008). A recent review by the EBMT reports encouraging
results in 51 children and adolescents with chemosensitive HL
who received RIC AlloSCT (Claviez et al., Blood, 2009). How-
ever, 63% of these patients had already failed MAC AutoSCT,
reducing the number of pts who were chemosensitive prior to
RIC AlloSCT.
Objective: We prospectively evaluated the safety and efficacy of
MAC AutoSCT followed by RIC AlloSCT in CAYA with poor-
risk HL.
Methods: Poor-risk HL pts achieving CR, PR, or SD after re-induc-
tion were eligible to receive CBV conditioning (Harris/Cairo, ASH,
2004) followed by RIC with busulfan (6.4 mg/kg), fludarabine
(180 mg/m2)6R-ATG(forunrelatedSCT).GVHDprophylaxis con-
sisted of MMF and tacrolimus as we have previously described
(Osunkwo/Cairo et al., BBMT, 2004), with discontinuation of MMF
on day 30/60 (related/unrelated AlloSCT) and a 4-6 week tacrolimus
taper.
Results: Ten pts, median age 18.4 (range 12.3-21.8), M/F 6/4 and
disease status atMACAutoSCTCR (5), PR (3), SD (2). Two refused
RIC AlloSCT; of the 8 allografts, 1 related/7 unrelated, 5 UCBT/3
PBSC,HLAmatching 6/6 (1), 5/6 (1), 4/6 (5), 8/10 (1), medianTNC
dose 0.35108/kg (0.09-6.13) and CD34 0.59106/kg (0.04-5.30).
All pts (n5 8) engrafted neutrophils following RIC AlloSCT at
median day 19 (15-45). Six of 7 evaluable pts engrafted platelets at
median day 46 (11-170). The probability of $grade II acute
GVHD was 37.5% (95% CI 0-63%) and of chronic GVHD 30%
(0-58%). Patients achieved median percent donor chimerism of
100%, 100% and 98%, on days 100, 180 and 365, respectively. Prob-
abilities of 1-year and 2-year OS (all, n5 10) were 90% (73-100%)
and 80% (59-100%) respectively. Three pts died on days 338, 370
and 746 of varicella, progressive HL and chronic GVHD/aspergillo-
sis, respectively. Seven pts are currently living at a median follow-up
of 2191 days.
Conclusions MAC AutoSCT followed by RIC AlloSCT for CAYA
with poor-risk HL is feasible and results in excellent early OS. Long-
term follow-up and a larger cohort are needed to determine whether
this approach improves 10-year EFS compared to MAC AutoSCT
alone.70
SINGLE CENTRE EXPERIENCE OF HEMATOPOEITIC STEM CELL TRANS-
PLANTATION FOR PATIENTS WITH COMPLEX AUTOIMMUNE ENTEROP-
ATHIES
Nademi, Z.1, Slatter, M.1, Barge, D.2, Hodges, S.3, Thomas, J.3,
Harvey, H.1, Hambleton, S.1, Flood, T.1, Cant, A.1, Abinun, M.1,
Gennery, A.1 1Newcastle upon Tyne Hospitals NHS Foundation Trust,
Newcastle upon Tyne, United Kingdom; 2Newcastle upon Tyne Hospitals
NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; 3New-
castle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon
Tyne, United Kingdom
Background: Complex autoimmune enteropathies encompass
a wide range of disorders including X-linked immune dysregulation,
polyendocrinopathy, enteropathy (IPEX) syndrome with FOXP3
gene mutation, IPEX-like syndrome (similar features as IPEX with-
out gene mutation) and other unclassified autoimmune enteropa-
thies.
Method: A retrospective study of patients with complex autoim-
mune enteropathies who underwent hematopoeitic stem cell trans-
plantation (HSCT) at Newcastle General Hospital, one of two
nationally designated centres for such procedures in the UK, was
performed.
Results: 13 patients were identified who fulfilled the inclusion crite-
ria; 2 (15%) IPEX, 8 (62%) IPEX-like and 3 (23%) unclassified au-
toimmune enteropathy. Median age at the time of HSCT was 2.5
years, ranged between 5 months to 19.5 years old. 9/13 (69%) pa-
tients were male. All underwent HSCT with 10/13 (77%) unrelated
(URD) including 3 cord transplant, and 3/13 (23%) matched sibling
(MSD). The conditioning regimen used was Fludarabine/Melphalan
in 6 (46.2%), Busulfan/Cyclophosphamide in 3 (23%), Treosulfan/
Cyclophosphamide in 2 (15.4%) and Treosulfan/Fludarabine in 2
(15.4%). 100% donor chimerism was achieved in 10 (77%) patients
including one after the unconditioned boost infusion 27 days post
HSCT. 3 (23%) patients have mixed donor chimerism with 60%
donor T cells. Ten (80%) patients are alive with resolution of enter-
opathy and have discontinued immunosuppression, one remains an
inpatient after HSCT about 100 days ago. 5/13 (38%) patients had
no graft versus host disease (GvHD) and 6/13 (46%) had only grade
II-III skin GvHD. Two (15%) died from complications related to
treatment of grade III skin and gut GvHD.
Conclusion:HSCT can be curative in patients with severe complex
autoimmune enteropathy. GvHD is a common significant complica-
tion which can be life threatening.71
SUCCESSFUL HALF-DOSE BUSULFAN/FULL-DOSE FLUDARABINE BASED
REDUCED INTENSITY CONDITIONING IN HIGH-RISK PEDIATRIC AND
ADULT CHRONIC GRANULOMATOUS DISEASE (CGD) PATIENTS
Gu¨ngo¨r, T.1, Schanz, U.2, Seger, R.1, Albert, M.3, Hassan, M.4 1Univer-
sity Children’s Hospital, Zu¨rich, Switzerland; 2University Hospital Zu¨r-
ich, Zu¨rich, Switzerland; 3Von Hauner’sche Kinderklinik, Mu¨nich,
Germany; 4Karolinska University Hospital, Huddinge, Sweden
Objective: To examine the feasibility, safety and efficacy of he-
matopoietic stem cell transplantation (HSCT) in high-risk pedi-
atric and adult patients with chronic granulomatous disease
(CGD) using a low-toxicity conditioning regimen based on
half-dosed (50-60%) Busulfan, full-dose Fludarabine and in-vivo
T-cell depletion.
Patients andMethods: 11CGDpatients (5, 7, 12, 13, 17, 18, 20, 23,
29, 35 and 39 ys; n5 8 gp91-phox, n5 2 p22-phox and n5 1 p47
phox deficient) are described. All patients were therapy-refractory
to conventional treatment suffering from infectious and/or inflam-
matory complications at HSCT, e.g. colitis, active infection (Asper-
gillus, Neisseria, Actinomyces, Staph. aureus) or had former lung
aspergillosis. Stem cell donors consisted of 5 matched sibling, 4
MUD (10/10) and 2 MMUD (9/10) donors. Conditioning included
180 mg/qm Fludarabine (d -8 to -3), oral/iv. Busulfan (6.4-12 mg/
kg; d -4 to -2; in pediatric patients with adjusted Busulfan kinetics)
and Antithymocyte-Globulin Fresenius (4  10 mg/kg; d -4 to -1).
In 4 patients (5, 7, 12 and 17 ys) receiving MUD or MMUD trans-
plants, ATG-Fresenius was replaced by 0.5 mg/kg Alemtuzumab
(Campath IH) (d -8 to -6). As stem cell source, bone marrow (2.3
to 6.0  10 6 CD34/kg) was used in the majority of cases (n5 10),
